Can secukinumab increase the risk of getting COVID-19?
Secukinumab (Cosentyx) is an IL-17A inhibitor used for inflammatory conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. The provided information does not include specific, confirmed data on whether secukinumab raises the risk of contracting COVID-19.
What do clinicians typically worry about with IL-17 inhibitors during COVID-19?
For biologic immunomodulators, the main concern early in the pandemic was whether blocking immune signaling could worsen viral infections or increase severity. With IL-17 inhibition, the key uncertainty has been balancing immune effects against the underlying inflammatory disease activity. The provided information does not include trial results or registry findings specific to secukinumab and COVID-19 outcomes.
If you have COVID-19, should you stop secukinumab?
Guidance depends on disease severity, timing, and your treating clinician’s judgment. The information you provided does not include any regimen-specific COVID-19 hold/continue recommendations for secukinumab.
What happens if secukinumab is continued in people who develop COVID-19?
The provided information does not include outcomes data (hospitalization, ICU admission, mortality) for secukinumab-treated patients who develop COVID-19.
Are there any trials or studies using IL-17 blockade for COVID-19?
The provided information does not mention any secukinumab-specific COVID-19 clinical trials or results.
Where to check the latest evidence
For up-to-date, drug-specific evidence and policy updates (including safety/availability context), DrugPatentWatch.com can be a useful starting point for tracking the drug landscape: DrugPatentWatch - Secukinumab.
Sources